Clinical implications of immune reconstitution following hematopoietic stem cell transplantation

Karl S. Peggs, Aviva C. Krauss, Crystal L. MacKall

Research output: Chapter in Book/Report/Conference proceedingChapter

4 Scopus citations


The evolution of understanding regarding key issues involved in immune reconstitution should allow movement from indirect supportive care of immuno-incompetence following HSCT to proactive measures designed to enhance reconstitution in this setting. Future clinical studies using lymphoid progenitors, thymoprotective agents and immunostimulatory cytokines are needed to test the clinical utility of these approaches and agents which have had promising results in preclinical models. Importantly, while solid pre-clinical supporting data exist for many agents and approaches, clinical application mustproceed carefully, with particular attention to issues that may depend critically on timing and dose. Allogeneic HSCT presents a challenging arena for the application of immune based therapies because of the need to respect the delicate balance between GvHD, GvT responses, rejection and reconstitution of specific immunity against pathogens. Armed with our current and rapidly evolving knowledge, it is hopes that the coming years will witness the evolutionary development of clinical practice in this arena.

Original languageEnglish (US)
Title of host publicationHematopoietic Stem Cell Transplantation
PublisherSpringer Netherlands
Number of pages24
ISBN (Print)9780387785790
StatePublished - 2009
Externally publishedYes

Publication series

NameCancer Treatment and Research
ISSN (Print)0927-3042

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Clinical implications of immune reconstitution following hematopoietic stem cell transplantation'. Together they form a unique fingerprint.

Cite this